Who Qualifies for Keytruda Treatment?
Keytruda, also known as pembrolizumab, is a prescription medication used to treat various types of cancer, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, kidney cancer, bladder cancer, and Hodgkin lymphoma [1]. It belongs to a class of medications called checkpoint inhibitors, which work by boosting the body's immune system to fight cancer cells.
Keytruda Dosage by Cancer Type
The Keytruda dosage does vary based on cancer type and other factors, such as the patient's age, body weight, and overall health.
* For NSCLC, Keytruda is typically given at a dose of 200 mg every 3 weeks. However, a lower dose of 100 mg may be used for patients with severe kidney impairment [2].
* For melanoma, Keytruda is administered at a dose of 2 mg/kg (about 200-400 mg) every 3 weeks [3].
* For head and neck cancer, Keytruda is given at a dose of 200 mg every 3 weeks.
* For kidney cancer, the typical dosage is 200 mg every 3 weeks.
* For bladder cancer, Keytruda is administered at a dose of 200 mg every 3 weeks.
How to Get Started with Keytruda Treatment
Before starting Keytruda treatment, it's essential to discuss your specific situation with your doctor. They will help determine the best course of treatment for your cancer type and develop a treatment plan tailored to your needs. Your healthcare provider will also monitor you for potential side effects and adjust the dosage as needed [4].
What Happens if I Miss a Dose or Experience Side Effects?
If you miss a dose of Keytruda, take it as soon as possible. However, if it's almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule [5]. If you experience any side effects, inform your doctor right away. Some common side effects of Keytruda include fatigue, rash, diarrhea, and itching [6].
Sources:
[1] National Cancer Institute. (2022). Pembrolizumab.
[2] Merck & Co. (2022). Keytruda Prescribing Information.
[3] National Comprehensive Cancer Network. (2022). Melanoma.
[4] American Cancer Society. (2022). Immunotherapy: What You Need to Know.
[5] MedlinePlus. (2022). Pembrolizumab.
[6] FDA. (2022). Keytruda Medication Guide.
Note: This response is for informational purposes only and should not be considered a substitute for professional medical advice. Always consult your healthcare provider for personalized guidance and treatment recommendations.